Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Hematopoietic Cell Mobilization for Gene Therapy of Adult Patients with Severe Beta-Thalassemia: The Challenge of Splenectomy and the Role of Plerixafor

Evangelia Yannaki, MD, Thalia Papayannopoulou, Erica Jonlin, PhD, Fani Zervou, Garyfalia Karponi, Angeliki Xagorari, PhD, Pamela S. Becker, MD, PhD, Nikoleta Psatha, Ioannis Batsis, MD, Panayotis Kaloyannidis, MD, Varvara Tahynopoulou, Varnavas Constantinou, Asimenia Bouinta, Konstantia Kotta, Aglaia Athanassiadou, PhD, Achilles Anagnostopoulos, Athanasios Fassas, MD, George Stamatoyannopoulos, MD, DSci

Blood (2011) 118 (21): 166.

https://doi.org/10.1182/blood.V118.21.166.166

Published: 2011

Journal Articles

Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study

Blood (2010) 116 (21): 2322.

https://doi.org/10.1182/blood.V116.21.2322.2322

Published: 2010

Journal Articles

The Combination of AMD3100 + G-CSF Restores the Ineffective Hematopoietic Stem Cell Mobilization with G-CSF Alone in a Thalassemic Mouse Model.

Evangelia Yannaki, MD, Nikoleta Psatha, PhD, student, Maria Demertzi, BS, Evangelia Athanasiou, MD, Eleni Sgouramali, Student, Dimitris Bougiouklis, BS, Minas Arsenakis, Prof, Achilles Anagnostopoulos, MD, Athanasios Fassas, MD

Blood (2009) 114 (22): 3234.

https://doi.org/10.1182/blood.V114.22.3234.3234

Published: 2009

Journal Articles

Limitations of G-CSF Mobilization in Splenectomized Patients with Beta-Thalassemia Major: Implications for Thalassemia Gene Therapy.

Evangelia Yannaki, MD, Thalia Papayannopoulou, MD, Erica Jonlin, PhD, Ioannis Batsis, MD, Pamela S. Becker, MD, PhD, Fani Zervou, BS, Angeliki Xagorari, PhD, Garyfalia Karponi, BS, Varvara Tahynopoulou, BS, Panayotis Kaloyannidis, MD, Varnavas Constantinou, MD, Achilles Anagnostopoulos, MD, Athanasios Fassas, MD, George Stamatoyannopoulos, MD, DSci

Blood (2009) 114 (22): 2150.

https://doi.org/10.1182/blood.V114.22.2150.2150

Published: 2009

Journal Articles

Dose and Timing Limitations in the Use of Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Experimental Arthritis.

Evangelia Yannaki, MD, Anastasia Papadopoulou, PhD student, Minas Yiangou, PhD, Evangelia Athanasiou, MD, Argyrw Paraskeva, BS, Ioannis Batsis, MD, Eleftheria Tsolaki, PhD student, Angeliki Xagorari, PhD, Achilles Anagnostopoulos, MD, Athanasios Fassas, MD

Blood (2008) 112 (11): 2326.

https://doi.org/10.1182/blood.V112.11.2326.2326

Published: 2008

Journal Articles

Rheumatoid Arthritis as a New Disease-Target for Bortezomib.

Evangelia Yannaki, MD, Anastasia Papadopoulou, PhD student, Argyrw Paraskeva, BS, Panayotis Kaloyannidis, MD, Evangelia Athanasiou, MD, Dimitris Bougiouklis, BS, Panayotis Palladas, MD, Minas Yiangou, PhD, Athanasios Fassas, MD, Achilles Anagnostopoulos

Blood (2008) 112 (11): 1543.

https://doi.org/10.1182/blood.V112.11.1543.1543

Published: 2008

Journal Articles

Intravenous Busulfan-Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML - An ALWP-EBMT Survey.

Arnon Nagler, MD, Myriam Labopin, MD, Avichai Shimoni, MD, Donald Bunjes, MD, Pedro Pimentel, MD, Gerard Socie, MD, Karim Boudjedir, MD, Axel R. Zander, MD, A. Torres Gomez, MD, Michele Baccarini, MD, Hakan Goker, MD, Athanasios Fassas, MD, Chantal Kenzey, Benedicte Samey, Zouabi Hamadi, MD, Vanderson Rocha, MD

Blood (2007) 110 (11): 1995.

https://doi.org/10.1182/blood.V110.11.1995.1995

Published: 2007

Journal Articles

Outcome of Patients with Primary Refractory Acute Myeloid Leukemia (AML) Undergoing Myeloablative Allogeneic Stem-Cell Transplantation (alloSCT) from HLA-Identical Sibling: Favorable Outcome in a Subset of Patients.

Jordi Esteve, MD, Myriam Labopin, MD, Gerhard Ehninger, MD, Athanasios Fassas, MD, Jurgen Finke, MD, Miguel A. Sanz, MD, Paolo Alessandrino, MD, Axel Arthur Fauser, MD, Vanderson Rocha, MD

Blood (2006) 108 (11): 3022.

https://doi.org/10.1182/blood.V108.11.3022.3022

Published: 2006

Journal Articles

Immunized Against Hepatitis B Virus Allografted Recipients Are at High Risk for Gradual Surface Antibody (HbsAb) Disappearance Post Transplant, Regardless of Adoptive Immunity Transfer: A Study of 82 Allografted Long Term Survivors.

Panayotis Kaloyannidis, MD, Evangelia Yannaki, MD, Ioannis Batsis, MD, Despoina Adamidou, MD, Demetrios Bartzoudis, MD, Maria Papathanasiou, MD, Despoina Mallouri, MD, Ioanna Sakellari, MD, Athanasios Fassas, MD, Achilles Anagnostopoulos, MD

Blood (2006) 108 (11): 2862.

https://doi.org/10.1182/blood.V108.11.2862.2862

Published: 2006

Journal Articles

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Klaus Hollmig, MD, Athanasios Fassas, MD, Erik Rasmussen, Raymond Thertulien, MD, PhD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 1480.

https://doi.org/10.1182/blood.V104.11.1480.1480

Published: 2004

Journal Articles

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampalamo Talamo, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Frits van Rhee, MD, PhD, Athanasios Fassas, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 929.

https://doi.org/10.1182/blood.V104.11.929.929

Published: 2004

Journal Articles

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Athanasios Fassas, MD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Julian Terry, Maurizio Zangari, MD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 932.

https://doi.org/10.1182/blood.V104.11.932.932

Published: 2004

Journal Articles

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Maurizio Zangari, MD, Athanasios Fassas, MD, Julie Stover, Teresa Milner, Erik Rasmussen, Elias Anaissie, MD, PhD, Choon-Kee Lee, MD, Klaus Hollmig, MD, Giampaolo Talamo, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 934.

https://doi.org/10.1182/blood.V104.11.934.934

Published: 2004

Journal Articles

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Guido Tricot, MD, PhD, John Crowley, PhD, Julie Stover, BA, Teresa Milner, BS, Athanasios Fassas, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Elias Anaissie, MD, Frits van Rhee, MD, PhD, Giampalamo Talamo, MD, Klaus Hollmig, MD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 936.

https://doi.org/10.1182/blood.V104.11.936.936

Published: 2004

Journal Articles

Pathogenetic Implications from the Analysis of Immunoglobulin Genes in Chronic Lymphocytic Leukemia of Mediterranean Ancestry: The Lesson of the IGHV3-21 Gene.

Paolo Ghia, MD, PhD, Kostas Stamatopoulos, MD, Chrysoula Belessi, MD, Carol Moreno, MD, Stefania Stella, PhD, Giuseppe Guida, MD, Ariane Michel, PhD, Marta Crespo, PhD, Nikolaos Laoutaris, MD, Emili Montserrat, MD, Achilles Anagnostopoulos, MD, Guillaume Dighiero, MD, Athanasios Fassas, MD, Federico Caligaris-Cappio, MD, Frederic Davi, PhD

Blood (2004) 104 (11): 771.

https://doi.org/10.1182/blood.V104.11.771.771

Published: 2004

Journal Articles

Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Jeffrey Sawyer, PhD, Clyde Bailey, Maureen Reiner, Erik Rasmussen, Athanasios Fassas, MD, Maurizio Zangari, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 940.

https://doi.org/10.1182/blood.V104.11.940.940

Published: 2004

Journal Articles

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Blood (2004) 104 (11): 784.

https://doi.org/10.1182/blood.V104.11.784.784

Published: 2004

Journal Articles

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Choon-Kee Lee, MD, Annick E. Tricot, Athanasios Fassas, MD, Elias Anaissie, MD, Klaus Hollmig, MD, Raymond Thertulien, MD, Giampaolo Talamo, MD, Frits van Rhee, MD, PhD, Julie M. Stover, BA, Louis Fink, MD, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 4914.

https://doi.org/10.1182/blood.V104.11.4914.4914

Published: 2004

Journal Articles

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampaolo Talamo, MD, Athanasios Fassas, MD, Choon-Kee Lee, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 2399.

https://doi.org/10.1182/blood.V104.11.2399.2399

Published: 2004

Journal Articles

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

John Shaughnessy, PhD, Frank Zhan, PhD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Lisa Jackson, Athanasios Fassas, MD, Maurizio Zangari, MD, Choon-Kee Lee, MD, Giampaolo Talamo, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 4935.

https://doi.org/10.1182/blood.V104.11.4935.4935

Published: 2004

NARROW

Hematopoietic Cell Mobilization for Gene Therapy of Adult Patients with Severe Beta-Thalassemia: The Challenge of Splenectomy and the Role of Plerixafor

Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study

The Combination of AMD3100 + G-CSF Restores the Ineffective Hematopoietic Stem Cell Mobilization with G-CSF Alone in a Thalassemic Mouse Model.

Limitations of G-CSF Mobilization in Splenectomized Patients with Beta-Thalassemia Major: Implications for Thalassemia Gene Therapy.

Dose and Timing Limitations in the Use of Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Experimental Arthritis.

Rheumatoid Arthritis as a New Disease-Target for Bortezomib.

Intravenous Busulfan-Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML - An ALWP-EBMT Survey.

Outcome of Patients with Primary Refractory Acute Myeloid Leukemia (AML) Undergoing Myeloablative Allogeneic Stem-Cell Transplantation (alloSCT) from HLA-Identical Sibling: Favorable Outcome in a Subset of Patients.

Immunized Against Hepatitis B Virus Allografted Recipients Are at High Risk for Gradual Surface Antibody (HbsAb) Disappearance Post Transplant, Regardless of Adoptive Immunity Transfer: A Study of 82 Allografted Long Term Survivors.

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Pathogenetic Implications from the Analysis of Immunoglobulin Genes in Chronic Lymphocytic Leukemia of Mediterranean Ancestry: The Lesson of the IGHV3-21 Gene.

Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only